Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you've searched for 'sigma semaglutide', you've likely encountered the term used online as slang for semaglutide — the active ingredient in the licensed UK weight-loss injection Wegovy. Semaglutide is a prescription-only medicine that can only be dispensed following a clinical assessment by a qualified prescriber. No single search term changes that legal reality. What you may genuinely want to know is how semaglutide works, who it's licensed for, and what the clinical evidence actually says — so that's where this page starts. A prescriber, not an algorithm, decides whether it's appropriate for you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The phrase has spread through social media, gym forums and fitness communities, often implying that semaglutide sourced or framed in a particular way is somehow more potent, more exclusive or differently formulated. It isn't. There is one licensed semaglutide molecule. The UK medicine approved for weight management is Wegovy, manufactured by Novo Nordisk. Its composition, dosing schedule and clinical evidence base are fixed in the product's Summary of Product Characteristics, which you can read in full on the Electronic Medicines Compendium.
The 'sigma' label is internet shorthand, nothing more. It carries no regulatory meaning and does not correspond to a separate product, a higher dose, a different formulation or a supplier tier. Anyone selling something described that way as though it were distinct from standard licensed semaglutide is, at best, using marketing language; at worst, they may be supplying a medicine through an unverified route. The MHRA has warned repeatedly about fake and illegally traded weight-loss medicines, if a seller's terminology doesn't match the licensed product name, that's a reason to pause, not proceed.
Semaglutide obtained through a legitimate route is the same compound every time: verified, manufactured to pharmaceutical standards, and supplied against a prescription written by a qualified clinician.
Semaglutide is a GLP-1 receptor agonist. GLP-1 is a hormone your gut releases after eating; it signals fullness to the brain, prompts the pancreas to release insulin in proportion to blood sugar, and slows gastric emptying so food moves through more gradually. Semaglutide mimics that hormone and prolongs its effect. The result, for most people, is a meaningful reduction in appetite and a lower drive to eat between meals.
This is a biological mechanism, not a willpower hack. Many people find that food noise (the persistent mental chatter about eating) quietens considerably on treatment. That's not a marketing claim; it's how the receptor pathway works, and it's part of why the STEP 1 trial results, published in the New England Journal of Medicine, showed average weight reductions of around 15% over 68 weeks at the 2.4mg maintenance dose, roughly three times what lifestyle intervention alone produced in the same trial.
The medicine is given as a once-weekly subcutaneous injection. Treatment begins at a low dose to allow the body to adjust, and the prescriber titrates upward, typically in monthly steps, to the maintenance dose. The full semaglutide overview on this site covers the dose pathway in more detail.
Wegovy is licensed in the UK for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. Those are the licence parameters; meeting them doesn't automatically mean treatment is right for you, that's why a prescriber reviews every consultation individually.
It's also worth being clear about what Ozempic is. It contains the same active ingredient but holds a licence for type 2 diabetes management, not weight loss. The two are not interchangeable by design, and this page explains the Ozempic and Wegovy distinction in full. The NHS does not recommend Ozempic for weight management.
On the NHS, access to Wegovy runs through specialist weight management services under NICE technology appraisal TA875, which sets specific criteria including multidisciplinary support and a maximum treatment duration of two years. Waiting lists for those services can be long. Private treatment through a GPhC-registered pharmacy is a separate, lawful route, subject to clinical suitability assessed by a qualified prescriber at the time of consultation.
Most of the side effects people experience with semaglutide are gastrointestinal: nausea, loose stools, constipation, indigestion and burping are the most commonly reported. They tend to be most noticeable in the first weeks of a new dose and often ease as the body adjusts, and you can find a closer look at how people typically get on with the sema semaglutide experience on this site. Eating smaller portions, avoiding very fatty foods and staying well hydrated all help, though personal advice should come from the prescriber who knows your full picture.
A small number of people experience more significant effects. The MHRA has highlighted acute pancreatitis as an infrequent but serious possibility: severe, persistent stomach pain (especially pain that spreads toward the back) warrants urgent medical attention and should not be managed with over-the-counter remedies while waiting for it to pass. Suspected side effects can be reported directly through the MHRA Yellow Card scheme.
Semaglutide is not recommended during pregnancy, while breastfeeding, or for anyone actively trying to conceive, and it is not licensed for under-18s. Women using the oral contraceptive pill should discuss contraception with their prescriber before starting, as absorption of the pill may be affected during treatment. If you're weighing up whether semaglutide or a different treatment suits your situation, our treatment options page is a practical starting point, and our clinical team is available to discuss your individual circumstances. For those curious about cost context before deciding, the weight loss overview covers what private treatment typically involves.
One practical note: if you're thinking about timing your first consultation around a monthly budget, payday, or before a holiday, that's entirely reasonable, and it can also be worth reviewing the semaglutide 1 dosing information and the semaglutide 2 dosing information ahead of your consultation so you have a clear sense of how the titration schedule progresses. Just be aware that, once approved, same-day dispatch is available for orders placed before 12pm on working days, so you're not locked into any particular week to get started.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.